Cytokine expression in allergic inflammation: Systematic review of in vivo challenge studies

Mediators of Inflammation

Volumn 12, Issue 5, 2003, Pages 259-267

  Ferreira, Manuel A R ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Allergen challenge; Allergy; Cytokine; Inflammation

Indexed keywords

ALLERGEN; CHEMOKINE; EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ALLERGY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ATOPY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RECEPTOR UPREGULATION; REVIEW; TARGET CELL;

ALLERGENS; CYTOKINES; HUMANS; HYPERSENSITIVITY;

EID: 0242610875     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350310001619717     Document Type: Review

References (183)

1. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 9: 813-824.
2. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; 6760 (Suppl): B12-B17.
3. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 9: 825-857.
4. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 3: 604-612.
5. Yamaguchi Y, Hayashi Y, Sugama Y, et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 1988; 5: 1737-1742.
6. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol 1997; 12: 5791-5796.
7. Cassatella MA, Guasparri I, Ceska M, Bazzoni F, Rossi F. Interferon-gamma inhibits interleukin-8 production by human polymorphonuclear leucocytes. Immunology 1993; 2: 177-184.
8. Purkerson JM, Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J Exp Med 1992; 4: 973-982.
9. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 8: 3730-3734.
10. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 11: 3796-3806.
11. Peters SP, Zangrilli JG, Fish JE. Late phase allergic reactions. In: Middleton et al., eds. Allergy: principles and practice. St Louis: Mosby, 1998: 342-355.
12. Broide DH, Firestein GS. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest 1991; 3: 1048-1053.
13. Kay AB, Ying S, Varney V, et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 3: 775-778.
14. Barata LT, Ying S, Meng Q, et al. IL-4-and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Allergy Clin Immunol 1998; 2: 222-230.
15. Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993; 1: 35-42.
16. Berin MC, Eckmann L, Broide DH, Kagnoff MF. Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 2001; 4: 382-389.
17. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995; 6: 1900-1906.
18. Bradding P, Mediwake R, Feather IH, et al. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. Clin Exp Allergy 1995; 5: 406-415.
19. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 3: 469-476.
20. Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998; 2: 137-146.
21. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001; 4: 881-886.
22. Cameron LA, Durham SR, Jacobson MR, et al. Expression of IL-4, Cepsilon RNA, and lepsilon RNA in the nasal mucosa of patients with seasonal rhinitis: effect of topical corticosteroids. J Allergy Clin Immunol 1998; 3: 330-336.
23. Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure. J Allergy Clin Immunol 2000; 5: 904-910.
24. Christodoulopoulos P, Wright E, Frenkiel S, Luster A, Hamid Q. Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: effect of topical corticosteroids. J Allergy Clin Immunol 1999; 6: 1036-1044.
25. de Blay F, Krieger P, Spirlet F, et al. Repeated inhalation of low doses of cat allergen that do not induce clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels. Int Arch Allergy Immunol 1999; 2: 158-165.
26. Diaz-Sanchez D, Jyrala M, Ng D, Nel A, Saxon A. In vivo nasal challenge with diesel exhaust particles enhances expression of the CC chemokines rantes, MIP-1alpha, and MCP-3 in humans. Clin Immunol 2000; 2: 140-145.
27. Diaz-Sanchez D, Tsien A, Fleming J, Saxon A. Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed-specific IgE and skews cytokine production to a T helper cell 2-type pattern. J Immunol 1997; 5: 2406-2413.
28. Djukanovic R, Feather I, Gratziou C, et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996; 6: 575-581.
29. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 7: 468-475.
30. Durham SR, Ying S, Varney VA, et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 8: 2390-2394.
31. Durham SR, Gould HJ, Thienes CP, et al. Expression of epsilon germline gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 1997; 11: 2899-2906.
32. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 6: 1356-1365.
33. Eldridge MW, Peden DB. Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2000; 3: 475-481.
34. Fernvik E, Gronneberg R, Lundahl J, et al. Characterization of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma. Clin Exp Allergy 1999; 11: 1516-1525.
35. Fernvik E, Hallden G, Lundahl J, et al. Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. Allergy 1999; 5: 455-463.
36. Ghaffar O, Laberge S, Jacobson MR, et al. IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Am J Respir Cell Mol Biol 1997; 1: 17-24.
37. Ghaffar O, Christodoulopoulos P, Lamkhioued B, et al. In vivo expression of signal transducer and activator of transcription factor 6 (STAT6) in nasal mucosa from atopic allergic rhinitis: effect of topical corticosteroids. Clin Exp Allergy 2000; 1: 86-93.
38. Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages. Clin Exp Allergy 1997; 4: 379-388.
39. Gosset P, Malaquin F, Delneste Y, et al. Interleukin-6 and interleukin-1 alpha production is associated with antigen-induced late nasal response. J Allergy Clin Immunol 1993; 6: 878-890.
40. Greiff L, Petersen H, Mattsson E, et al. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. Clin Exp Allergy 2001; 8: 1321-1327.
41. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 2: 254-260.
42. Hasday JD, Meltzer SS, Moore WC, et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med 2000; 4: 1229-1236.
43. Haselden BM, Larche M, Meng Q, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol 2001; 3: 394-401.
44. Hoefakker S, Caubo M, van't Erve EH, et al. In vivo cytokine profiles in allergic and irritant contact dermatitis. Contact Dermatitis 1995; 4: 258-266.
45. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 1997; 5: 1377-1383.
46. Howie SE, Aldridge RD, McVittie E, Forsey RJ, Sands C, Hunter JA. Epidermal keratinocyte production of interferon-gamma immunoreactive protein and mRNA is an early event in allergic contact dermatitis. J Invest Dermatol 1996; 6: 1218-1223.
47. Huang SK, Xiao HQ, Kleine-Tebbe J, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995; 5: 2688-2694.
48. Jacobi HH, Poulsen LK, Reimert CM, et al. IL-8 and the activation of eosinophils and neutrophils following nasal allergen challenge. Int Arch Allergy Immunol 1998; 1: 53-59.
49. Julius P, Luttmann W, Knoechel B, Kroegel C, Matthys H, Virchow JC Jr. CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur Respir J 1999; 6: 1253-1259.
50. Kato M, Liu W, Hattori T, Nakashima I. Evidence of potential regulation by interleukin-4 of the soluble intercellular adhesion molecule 1 level in patients with seasonal allergic rhinitis under provocation by a small amount of natural allergen. Ann Otol Rhinol Laryngol 1998; 3: 232-235.
51. Kelly EA, Rodriguez RR, Busse WW, Jarjour NN. The effect of segmental bronchoprovocation with allergen on airway lymphocyte function. Am J Respir Crit Care Med 1997; 5: 1421-1428.
52. Khan LN, Kon OM, Macfarlane AJ, et al. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am J Respir Crit Care Med 2000; 4: 1377-1382.
53. Kita H, Jorgensen RK, Reed CE, et al. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol 2000; 3: 521-529.
54. Kleinjan A, Holm AF, Dijkstra MD, et al. Preventive treatment of intranasal fluticasone propionate reduces cytokine mRNA expressing cells before and during a single nasal allergen provocation. Clin Exp Allergy 2000; 10: 1476-1485.
55. KleinJan A, Dijkstra MD, Boks SS, Severijnen LA, Mulder PG, Fokkens WJ. Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. J Allergy Clin Immunol 1999; 3: 441-450.
56. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996; 5: 899-904.
57. Krug N, Erpenbeck VJ, Balke K, et al. Cytokine profile of bronchoalveolar lavage-derived CD4(+), CD8(+), and gammadelta T cells in people with asthma after segmental allergen challenge. Am J Respir Cell Mol Biol 2001; 1: 125-131.
58. Krug N, Cruikshank WW, Tschernig T, et al. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000; 1: 105-111.
59. Laberge S, Pinsonneault S, Varga EM, et al. Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J Allergy Clin Immunol 2000; 2: 293-301.
60. Laberge S, Durham SR, Ghaffar O, et al. Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J Allergy Clin Immunol 1997; 4: 569-574.
61. Lee CE, Neuland ME, Teaford HG, et al. Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J Allergy Clin Immunol 1992; 5: 1010-1020.
62. Lilly CM, Nakamura H, Belostotsky OI, et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001; 7: 1669-1675.
63. Linden M, Svensson C, Andersson E, Andersson M, Greiff L, Persson CG. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5. Am J Respir Crit Care Med 2000; 5: 1705-1708.
64. Linden M, Greiff L, Andersson M, et al. Nasal cytokines in common cold and allergic rhinitis. Clin Exp Allergy 1995; 2: 166-172.
65. Liu MC, Proud D, Lichtenstein LM, et al. Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. J Allergy Clin Immunol 2001; 1: 29-38.
66. Massey W, Friedman B, Kato M, et al. Appearance of granulocyte- macrophage colony-stimulating factor activity at allergen-challenged cutaneous late-phase reaction sites. J Immunol 1993; 3: 1084-1092.
67. Masuyama K, Till SJ, Jacobson MR, et al. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. J Allergy Clin Immunol 1998; 4: 610-617.
68. Masuyama K, Jacobson MR, Rak S, et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 2: 192-199.
69. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997; 6: 683-690.
70. Moore WC, Hasday JD, Meltzer SS, Wisnewski PL, White B, Bleecker ER. Subjects with mild and moderate asthma respond to segmental allergen challenge with similar, reproducible, allergen-specific inflammation. J Allergy Clin Immunol 2001; 6: 908-914.
71. Moqbel R, Ying S, Barkans J, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995; 10: 4939-4947.
72. Nakamura Y, Christodoulopoulos P, Cameron L, et al. Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge. J Allergy Clin Immunol 2000; 6: 1146-1152.
73. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 12: 3704-3713.
74. Nocker RE, Out TA, Weller FR, Mul EP, Jansen HM, van der Zee JS. Influx of neutrophils into the airway lumen at 4 h after segmental allergen challenge in asthma. Int Arch Allergy Immunol 1999; 1: 45-53.
75. Nonaka M, Nonaka R, Woolley K, et al. Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995; 6: 3234-3244.
76. Nopp A, Hallden G, Lundahl J, et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol 2000; 1: 101-109.
77. Nouri-Aria KT, Irani AM, Jacobson MR, et al. Basophil recruitment and IL-4 production during human allergen-induced late asthma. J Allergy Clin Immunol 2001; 2: 205-211.
78. Nouri-Aria KT, O'Brien F, Noble W, Jabcobson MR, Rajakulasingam K, Durham SR. Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6 h) predominantly by eosinophils. Clin Exp Allergy 2000; 12: 1709-1716.
79. Nouri-Aria KT, Masuyama K, Jacobson MR, et al. Granulocyte/macrophage- colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Int Arch Allergy Immunol 1998; 4: 248-254.
80. Peden DB, Setzer RW Jr, Devlin RB. Ozone exposure has both a priming effect on allergen-induced responses and an intrinsic inflammatory action in the nasal airways of perennially allergic asthmatics. Am J Respir Crit Care Med 1995; 5: 1336-1345.
81. Prieto J, Van Der Ploeg I, Roquet A, et al. Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation. Clin Exp Allergy 2001; 5: 791-800.
82. Proud D, Reynolds CJ, Lichtenstein LM, Kagey-Sobotka A, Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998; 7: 868-875.
83. Pullerits T, Linden A, Malmhall C, Lotvall J. Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis. Allergy 2001; 9: 871-877.
84. Rajakulasingam K, Hamid Q, O'Brien F, et al. RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am J Respir Crit Care Med 1997; 2: 696-703.
85. Raulf-Heimsoth M, Wirtz C, Papenfuss F, Baur X. Nasal lavage mediator profile and cellular composition of nasal brushing material during latex challenge tests. Clin Exp Allergy 2000; 1: 110-121.
86. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 2: 313-324.
87. Robinson DS, Tsicopoulos A, Meng Q, Durham S, Kay AB, Hamid Q. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. Am J Respir Cell Mol Biol 1996; 2: 113-117.
88. Saengpanich S, Assanasen P, deTineo M, Haney L, Naclerio RM, Baroody FM. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope 2002; 1: 47-52.
89. Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995; 3: 927-933.
90. Sur S, Kita H, Gleich GJ, Chenier TC, Hunt LW. Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. J Allergy Clin Immunol 1996; 6: 1272-1278.
91. Taborda-Barata L, Jacobson M, Walker S, et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996; 1: 68-78.
92. Terada N, Hamano N, Kim WJ, et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001; 4: 575-579.
93. Teran LM, Carroll MP, Shute JK, Holgate ST. Interleukin 5 release into asthmatic airways 4 and 24 hours after endobronchial allergen challenge: its relationship with eosinophil recruitment. Cytokine 1999; 7: 518-522.
94. Teran LM, Carroll M, Frew AJ, et al. Neutrophil influx and interleukin-8 release after segmental allergen or saline challenge in asthmatics. Int Arch Allergy Immunol 1995; 1-3: 374-375.
95. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schroder JM. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol 1996; 4: 1806-1812.
96. Teran LM, Carroll MP, Frew AJ, et al. Leukocyte recruitment after local endobronchial allergen challenge in asthma. Relationship to procedure and to airway interleukin-8 release. Am J Respir Crit Care Med 1996; 2: 469-476.
97. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 3: 828-837.
98. Thomassen MJ, Raychaudhuri B, Dweik RA, et al. Nitric oxide regulation of asthmatic airway inflammation with segmental allergen challenge. J Allergy Clin Immunol 1999; 6: 1174-1182.
99. Tsicopoulos A, Hamid Q, Haczku A, et al. Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. J Allergy Clin Immunol 1994; 4: 764-772.
100. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 2: 644-651.
101. Virchow JC Jr, Walker C, Hafner D, et al. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995; 4: 960-968.
102. Virchow JC Jr, Julius P, Matthys H, Kroegel C, Luttmann W. CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma. Eur Respir J 1998; 2: 317-323.
103. Wachholz PA, Nouri-Aria KT, Wilson DR, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 1: 56-62.
104. Wang M, Saxon A, Diaz-Sanchez D. Early IL-4 production driving Th2 differentiation in a human in vivo allergic model is mast cell derived. Clin Immunol 1999; 1: 47-54.
105. Wang JH, Duddle J, Devalia JL, Davies RJ. Nitrogen dioxide increases eosinophil activation in the early-phase response to nasal allergen provocation. Int Arch Allergy Immunol 1995; 1-3: 103-105.
106. Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 6: 971-976.
107. Woolley KL, Adelroth E, Woolley MJ, et al. Interleukin-3 in bronchial biopsies from nonasthmatics and patients with mild and allergen-induced asthma. Am J Respir Crit Care Med 1996; 1: 350-355.
108. Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995; 6: 1915-1924.
109. Wright ED, Christodoulopoulos P, Frenkiel S, Hamid Q. Expression of interleukin (IL)-12 (p40) and IL-12 (beta 2) receptors in allergic rhinitis and chronic sinusitis. Clin Exp Allergy 1999; 10: 1320-1325.
110. Ying S, Meng Q, Barata LT, Robinson DS, Durham SR, Kay AB. Associations between IL-13 and IL-4 (mRNA and protein), vascular cell adhesion molecule-1 expression, and the infiltration of eosinophils, macrophages, and T cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Immunol 1997; 10: 5050-5057.
111. Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995; 6: 2153-2159.
112. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 4: 694-700.
113. Ying S, Meng Q, Taborda-Barata L, et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 1996; 1: 70-76.
114. Ying S, Meng Q, Barata LT, Kay AB. Macrophage inflammatory protein-1alpha and C-C chemokine receptor-1 in allergen-induced skin late-phase reactions: relationship to macrophages, neutrophils, basophils, eosinophils and T lymphocytes. Clin Exp Allergy 2001; 11: 1724-1731.
115. Ying S, Robinson DS, Varney V, et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 6: 745-750.
116. Ying S, Durham SR, Jacobson MR, et al. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 2: 200-206.
117. Ying S, Durham SR, Barkans J, et al. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am J Respir Cell Mol Biol 1993; 4: 356-360.
118. Zweiman B, Kaplan AP, Tong L, Moskovitz AR. Cytokine levels and inflammatory responses in developing late-phase allergic reactions in the skin. J Allergy Clin Immunol 1997; 1: 104-109.
119. Alvarez-Puebla MJ, Olaguibel-Rivera JM, Urbiola-Marcilla E, Garcia BE, Tabar-Purroy AI. Determinants of allergen-induced late bronchial responses in mild asthmatics. Chest 2001; 1: 120-127.
120. Baroody FM, Rouadi P, Driscoll PV, Bochner BS, Naclerio RM. Intranasal beclomethasone reduces allergen-induced symptoms and superficial mucosal eosinophilia without affecting submucosal inflammation. Am J Respir Crit Care Med 1998; 3: 899-906.
121. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001; 6: 682-687.
122. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 4: 1414-1424.
123. Cameron L, Christodoulopoulos P, Lavigne F, et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol 2000; 3: 1538-1545.
124. Cameron L, Hamid Q, Wright E, et al. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. J Allergy Clin Immunol 2000; 1: 46-52.
125. Diaz-Sanchez D, Tsien A, Fleming J, Saxon A. Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge. Clin Immunol 1999; 3: 313-322.
126. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 1995; 5: 831-833.
127. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 12: 1178-1184.
128. Frew AJ, Teran LM, Madden J, et al. Cellular changes 24 hours after endobronchial allergen challenge in asthma. Int Arch Allergy Immunol 1995; 1-3: 376-377.
129. Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol 1997; 3: 259-265.
130. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 4: 561-571.
131. Gratziou C, Carroll M, Montefort S, Teran L, Howarth PH, Holgate ST. Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Am J Respir Crit Care Med 1996; 2: 515-520.
132. Hidi R, Riches V, Al-Ali M, et al. Role of B7-CD28/CTTA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES. J Immunol 2000; 1: 412-418.
133. Hiltermann TJ, de Bruijne CR, Stolk J, et al. Effects of photochemical air pollution and allergen exposure on upper respiratory tract inflammation in asthmatics. Am J Respir Crit Care Med 1997; 6: 1765-1772.
134. Jaffar Z, Roberts K, Pandit A, Linsley P, Djukanovic R, Holgate S. B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation. Am J Respir Cell Mol Biol 1999; 1: 153-162.
135. Jaffar ZH, Stanciu L, Pandit A, Lordan J, Holgate ST, Roberts K. Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta, T cells. J Immunol 1999; 11: 6283-6291.
136. Jahnsen FL, Lund-Johansen F, Dunne JF, Farkas L, Haye R, Brandtzaeg P. Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy. J Immunol 2000; 7: 4062-4068.
137. Kawaguchi M, Onuchic LF, Li XD, et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol 2001; 8: 4430-4435.
138. Kelly EA, Busse WW, Jarjour NN. Inhaled budesonide decreases airway inflammatory response to allergen. Am J Respir Crit Care Med 2000; 3: 883-890.
139. Krishnaswamy G, Liu MC, Su SN, et al. Analysis of cytokine transcripts in the bronchoalveolar lavage cells of patients with asthma. Am J Respir Cell Mol Biol 1993; 3: 279-286.
140. Langeveld-Wildschut EG, Bruijnzeel PL, Mudde GC, et al. Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol 2000; 5: 1008-1016.
141. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL) -4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy 1997; 11: 1292-1298.
142. Panina-Bordignon P, Papi A, Mariani M, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 2001; 11: 1357-1364.
143. Pawankar RU, Okuda M, Hasegawa S, et al. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Am J Respir Crit Care Med 1995; 6: 2059-2067.
144. Peebles RS Jr, Wagner EM, Liu MC, Proud D, Hamilton RG, Togias A. Allergen-induced changes in airway responsiveness are not related to indices of airway edema. J Allergy Clin Immunol 2001; 5: 805-811.
145. Prieto J, Lensmar C, Roquet A, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med 2000; 8: 806-814.
146. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin. Allergy 2001; 1: 58-64.
147. Schroeder JT, Lichtenstein LM, Roche EM, Xiao H, Liu MC. IL-4 production by human basophils found in the lung following segmental allergen challenge. J Allergy Clin Immunol 2001; 2: 265-271.
148. Tsicopoulos A, Hamid Q, Varney V, et al. Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol 1992; 7: 2058-2061.
149. Wang JH, Devalia JL, Duddle JM, Hamilton SA, Davies RJ. Effect of six-hour exposure to nitrogen dioxide on early-phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis. J Allergy Clin Immunol 1995; 5: 669-676.
150. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 5397: 2258-2261.
151. Wright ED, Christodoulopoulos P, Small P, Frenkiel S, Hamid Q. Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. Laryngoscope 1999; 4: 551-556.
152. Yamada N, Wakugawa M, Kuwata S, Nakagawa H, Tamaki K. Changes in eosinophil and leukocyte infiltration and expression of IL-6 and IL-7 messenger RNA in mite allergen patch test reactions in atopic dermatitis. J Allergy Clin Immunol 1996; 6: S201-S206.
153. Yamada N, Wakugawa M, Kuwata S, Yoshida T, Nakagawa H. Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. J Allergy Clin Immunol 1995; 6: 1069-1075.
154. Becherel PA, Chosidow O, Le Goff L, et al. Inducible nitric oxide synthase and proinflammatory cytokine expression by human keratinocytes during acute urticaria. Mol Med 1997; 10: 686-694.
155. Karlsson MG, Davidsson A, Viale G, Graziani D, Hellquist HB. Nasal messenger RNA expression of interleukins 2, 4, and 5 in patients with allergic rhinitis. Diagnosis Mol Pathol 1995; 2: 85-92.
156. Kato M, Liu MC, Stealey BA, et al. Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects. Lymphokine Cytokine Res 1992; 6: 287-292.
157. Sur S, Gleich GJ, Offord KP, et al. Allergen challenge in asthma: association of eosinophils and lymphocytes with interleukin-5. Allergy 1995; 11: 891-898.
158. Tang C, Rolland JM, Ward C, Quan B, Walters EH. Allergen-induced airway reactions in atopic asthmatics correlate with allergen-specific IL-5 response by BAL cells. Respirology 1997; 1: 45-55.
159. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 4: 1033-1079.
160. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 10: 4220-4224.
161. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 5: 1381-1386.
162. Nouri-Aria KT, Masuyama K, Jacobson MR, et al. Granulocyte/macrophage- colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Int Arch Allergy Immunol 1998; 4: 248-254.
163. Marini M, Vittori E, Hollemborg J, Mattoli S. Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. J Allergy Clin Immunol 1992; 5: 1001-1009.
164. Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science 1985; 4708: 16-22.
165. Silberstein DS, Owen WF, Gasson JC, et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 1986; 10: 3290-3294.
166. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 12: 3239-3246.
167. Nguyen CL, Bui JT, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother 2001; 5: 420-429.
168. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 6673: 245-252.
169. Shortman K, Heath WR. Immunity or tolerance? That is the question for dendritic cells. Nat Immunol 2001; 11: 988-989.
170. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 11: 1010-1017.
171. Funauchi M, Yoo BS, Nozaki Y, et al. Dysregulation of the granulocyte-macrophage colony-stimulating factor receptor is one of the causes of defective expression of CD80 antigen in systemic lupus erythematosus. Lupus 2002; 5: 317-321.
172. Kotsimbos AT, Humbert M, Minshall E, et al. Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma. J Allergy Clin Immunol 1997; 5: 666-672.
173. Dirksen U, Hattenhorst U, Schneider P, et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. Blood 1998; 4: 1097-1103.
174. Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002; 64: 775-802.
175. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997; 12: 3507-3516.
176. Yano K, Yamaguchi M, de Mora F, et al. Production of macrophage inflammatory protein-1alpha by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab Invest 1997; 2: 185-193.
177. Ying S, Robinson DS, Meng Q, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 7: 3976-3984.
178. Ying S, Meng Q, Barata LT, Kay AB. Macrophage inflammatory protein-1alpha and C-C chemokine receptor-1 in allergen-induced skin late-phase reactions: relationship to macrophages, neutrophils, basophils, eosinophils and T lymphocytes. Clin Exp Allergy 2001; 11: 1724-1731.
179. Andrew DP, Chang MS, McNinch J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998; 9: 5027-5038.
180. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). J Leukoc Biol 2000; 3: 400-404.
181. Salvi SS, Babu KS, Holgate ST. Is asthma really due to a polarized T cell response toward a helper T cell type 2 phenotype? Am J Respir Crit Care Med 2001; 8: 1343-1346.
182. Boushey HA, Fahy JV. Targeting cytokines in asthma therapy: round one. Lancet 2000; 9248: 2114-2116.
183. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 9248: 2144-2148.